China's Aier Eye Hospital Group and New Zealand's Objective Acuity (OAL) have signed a Strategic Cooperation Agreement. The parties will use their respective core competencies to develop and commercialise Objective Acuity Vision Tests in China.

The Agreement sets out that, AIER will assist OAL with the development and clinical testing of OAL's objective vision test for children. This will ultimately provide access for OAL's breakthrough technology in over 200 hospitals in Aier's network for children.

Existing visual acuity tests require a verbal response to the examiner, which can make it difficult to achieve an objective and accurate vision assessment. By comparison, OAL's technology requires no verbal interaction, which can significantly increase accuracy and accessibility to children.

Adam Podmore, OAL's CEO commented: "Partnering and working with leading eyecare provider Aier is an exciting step forward for the company. Time to market will be accelerated and as a consequence, so will relief for those children where ineffective vision problem detection tests have led to learning difficulties. This partnership with Aier is based on our shared mission to provide best in class detection of vision problems for all."

Dr. Li from the Aier Eye Hospital Group said: "Aier is excited to be partnering with Objective Acuity with their advanced vision testing technology to help identify vision problems in young children."

Objective Acuity is being advised by Innovator Capital the London based, specialist investment bank and China based EuSino Business Consulting.